

## Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Downloaded from <a href="http://aidsinfo.nih.gov/guidelines">http://aidsinfo.nih.gov/guidelines</a> on 7/28/2012 EST.

Visit the AIDS*info* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <a href="http://aidsinfo.nih.gov/e-news">http://aidsinfo.nih.gov/e-news</a>.

# HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Panel Roster (Last updated March 27, 2012; last reviewed March 27, 2012)

These Guidelines were developed by the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (a Working Group of the Office of AIDS Research Advisory Council).

#### Panel Co-Chairs

John G. Bartlett Johns Hopkins University, Baltimore, MD H. Clifford Lane National Institutes of Health, Bethesda, MD

Executive Secretary

Alice K. Pau National Institutes of Health, Bethesda, MD

Scientific Members

John T. Brooks
Centers for Disease Control and Prevention, Atlanta, GA
Deborah L. Cohan
University of California—San Francisco, San Francisco, CA

Eric Daar University of California–Los Angeles, Harbor-UCLA Medical Center,

Los Angeles, CA

Steven G. Deeks University of California–San Francisco, San Francisco, CA

Carlos del Rio Emory University, Atlanta, GA

Robert T. Dodge University of North Carolina, Chapel Hill, NC
Courtney V. Fletcher University of Nebraska Medical Center, Omaha, NE
Gerald Friedland Yale University School of Medicine, New Haven, CT

Joel E. Gallant Johns Hopkins University, Baltimore, MD
Stephen J. Gange Johns Hopkins University, Baltimore, MD
Christopher M. Gordon National Institutes of Health, Bethesda, MD

Roy M. Gulick Weill Medical College of Cornell University, New York, NY W. Keith Henry Hennepin County Medical Center & University of Minnesota,

Minneapolis, MN

Martin S. Hirsch Massachusetts General Hospital & Harvard Medical School, Boston, MA

Michael D. Hughes Harvard School of Public Health, Boston, MA Bill G. Kapogiannis National Institutes of Health, Bethesda, MD

Daniel R. Kuritzkes Brigham and Women's Hospital & Harvard Medical School, Boston, MA

Richard W. Price University of California—San Francisco, San Francisco, CA Michael Saag University of Alabama at Birmingham, AL

Paul Sax Brigham and Women's Hospital & Harvard Medical School, Boston, MA

Mark Sulkowski Johns Hopkins University, Baltimore, MD

Zelalem Temesgen Mayo Clinic, Rochester, MN

David A. Wohl University of North Carolina, Chapel Hill, NC

#### **Community Members**

Lei Chou Treatment Action Group, New York, NY

Paul Dalton San Francisco, CA Heidi Nass Madison, WI

Jeff Taylor AIDS Treatment Activists Coalition, Palm Springs, CA Nelson Vergel Program for Wellness Restoration, Houston, TX

#### Members Representing Department of Health and Human Services Agencies

Victoria Cargill National Institutes of Health, Rockville, MD

Laura Cheever Health Resources and Services Administration, Rockville, MD
Jonathan Kaplan Centers for Disease Control and Prevention, Atlanta, GA
Kendall Marcus Food and Drug Administration, Silver Spring, MD
Henry Masur National Institutes of Health, Bethesda, MD
Lynne Mofenson National Institutes of Health, Bethesda, MD

Kimberly Struble Food and Drug Administration, Silver Spring, MD

#### Non-Voting Observer

Monica Calderon National Institutes of Health, SAIC-Frederick, Inc., NCI-Frederick,

Frederick, MD

### Acknowledgement

The Panel would like to acknowledge the assistance of Sarita D. Boyd, Pharm.D., (Food and Drug Administration) for her assistance in updating the drug interaction tables and Satish Gopal, M.D., Ph.D., (University of North Carolina) and Ronald Mitsuyasu, M.D., (University of California—Los Angeles) for their assistance with the "Malignancies" discussion in Initiating Antiretroviral Therapy.